Published peptide research references
Linaclotide
Governed registry record
167 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.
Open the peptide evidence profile →Approved source records
A pharmacovigilance study of the association between linaclotide/plecanatide and muscle spasms based on food and drug administration adverse event reporting system.
DOI: 10.3389/fphar.2025.1635792PMID: 40843382
Source identity and connection checked by Codex (AI).
Application of oral sulfate solution combined with linaclotide in bowel preparation for colonoscopy.
DOI: 10.3389/fmed.2026.1696298PMID: 41889509
Source identity and connection checked by Codex (AI).
Clinical Study on the Application of Low-Dose 2L Lactulose Combined with Linaclotide in Bowel Preparation Before Colonoscopy
DOI: 10.21203/rs.3.rs-7391900/v1
Source identity and connection checked by Codex (AI).
Constipation-predominant irritable bowel syndrome treatment options Linaclotide, Lubiprostone, Plecanatide, and Tenapanor: analysis of the FDA Adverse Event Reporting System (FAERS) database.
DOI: 10.1080/14740338.2025.2519833PMID: 40503810
Source identity and connection checked by Codex (AI).
Efficacy and safety of Guanylyl cyclase C agonists (linaclotide and plecanatide) in patients with irritable bowel syndrome with constipation: a systematic review and meta-analysis of randomized controlled trials.
DOI: 10.3389/fphar.2026.1761301PMID: 42038325
Source identity and connection checked by Codex (AI).
Efficacy and safety of linaclotide plus polyethylene glycol for bowel preparation before colonoscopy in elderly Chinese patients: a systematic review and meta-analysis.
DOI: 10.3389/fmed.2026.1833539PMID: 42482900
Source identity and connection checked by Codex (AI).
Efficacy of Polyethylene Glycol Electrolyte Powder Combined with Linaclotide for Bowel Preparation for Colonoscopy in Children with Functional Constipation.
DOI: 10.1620/tjem.2026.j007PMID: 41780967
Source identity and connection checked by Codex (AI).
Efficacy of linaclotide as adjunct for bowel preparation in patients with chronic constipation: a pre-specified analysis of the APPLE trial.
DOI: 10.5946/ce.2026.214PMID: 42681900
Source identity and connection checked by Codex (AI).
Linaclotide for Bowel Preparation: Is "Afterload Reduction" Not Just for Heart Failure Anymore?
DOI: 10.14309/ajg.0000000000003375PMID: 40110861
Source identity and connection checked by Codex (AI).
Partially differentiated enterocytes in ileal and distal-colonic human F508del-CF-enteroids secrete fluid in response to forskolin and linaclotide
DOI: 10.1101/2025.02.03.636268
Source identity and connection checked by Codex (AI).
A post hoc analysis of linaclotide in pediatric patients with functional constipation and neurodevelopmental disorders.
2026
Adjunctive linaclotide improves bowel cleansing and patient experience in polyethylene glycol-based bowel preparation.
2026
Effect of 3-Day Linaclotide Administration to Reduce the Polyethylene Glycol Volume for Colonoscopy Bowel Preparation: A Multicenter, Noninferiority, Randomized Controlled Trial.
2026
Effect of Age and Age-Defined Menopausal Status on Linaclotide Efficacy and Safety in Adults With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation: Post Hoc Analyses of Phase 2b/3 Studies.
2026
Effect of Linaclotide on Colonic Motility Assessed With Intraluminal Colonic High-Resolution Manometry in Healthy Subjects. An Acute, Open Label, Randomized, Crossover, Reader-Blinded Study.
2026
Effect of linaclotide combined with polyethylene glycol on bowel preparation before colonoscopy in patients with constipation.
2026
Efficacy and Safety of Linaclotide in Pediatric Patients of Functional Constipation: A Meta-analysis of Randomized Controlled Trials.
2026
Efficacy safety of linaclotide combined with polyethylene glycol for bowel preparation in patients with constipation: a meta-analysis.
2026
Evaluating linaclotide for the treatment of functional constipation in children and adolescents.
2026
Evaluating linaclotide for the treatment of irritable bowel syndrome with constipation in children and adolescents.
2026
Identification and Quantification of Structurally Related Peptide Impurity in Linaclotide by Liquid Chromatography-High Resolution Mass Spectrometry.
2026
Linaclotide combined with polyethylene glycol for bowel preparation in colonoscopy: a systematic review and meta-analysis of randomized controlled trials.
2026
Linaclotide for irritable bowel syndrome with constipation: integrating realworld evidence into the therapeutic puzzle.
2026
Linaclotide in combination with compound polyethylene glycol powder enhances bowel preparation for colonoscopy in patients aged over 60 years: a multi-center, endoscopist-blind, randomized controlled trial.
2026
Short-term linaclotide plus polyethylene glycol in patients at increased risk of inadequate bowel preparation: A randomized, double-blind, multicenter trial.
2026
The Efficacy of Single Dose Linaclotide in Polyethylene Glycol-Based Bowel Preparation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
2026
Characterization of disulfide bridges containing cyclic peptide Linaclotide and its degradation products by using LC-HRMS/MS.
2025
Combined linaclotide and polyethylene glycol electrolyte for colonoscopy preparation: a network meta-analysis of 14 randomized controlled trials.
2025
Cost-Effectiveness of Vibrant System vs. Linaclotide in Chronic Idiopathic Constipation.
2025
Effects of the combined use of linaclotide and oral sulfate solution in bowel preparation for patients with chronic constipation undergoing colonoscopy: protocol of a prospective, randomised, controlled, single-blind clinical trial from a single centre in China.
2025
Efficacy and Safety of Linaclotide as an Adjunct to Polyethylene Glycol in Bowel Preparation: A Meta-Analysis.
2025
Efficacy of 1 L Polyethylene Glycol Plus Ascorbic Acid With Linaclotide Versus Senna for Bowel Preparation: A Multicenter, Endoscopist-Blinded, Randomized Controlled Trial (Apple Trial).
2025
Efficacy of Linaclotide in Functional Dyspepsia and Constipation-Predominant Irritable Bowel Syndrome Overlap: A Randomized Trial.
2025
Linaclotide Use for the Treatment of Constipation and Gastrointestinal Symptoms in People With Cystic Fibrosis.
2025
Real-world safety of linaclotide in Chinese patients with irritable bowel syndrome with constipation: a multicenter, single-arm, prospective observational study.
2025
Safety and efficacy of linaclotide as an adjuvant for bowel preparation: A systematic review and meta-analysis.
2025
Application of linaclotide in bowel preparation for colonoscopy in patients with constipation: A prospective randomized controlled study.
2024
Bowel preparation with linaclotide and 1 L polyethylene glycol plus ascorbic acid prior to colonoscopy in chronic constipated patients.
2024
Comparative profiles of lubiprostone, linaclotide, and elobixibat for chronic constipation: a systematic literature review with meta-analysis and number needed to treat/harm.
2024
DRA involvement in linaclotide-stimulated bicarbonate secretion during loss of CFTR function.
2024
Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
2024
Efficacy and safety of linaclotide in treatment-resistant chronic constipation: A multicenter, open-label study.
2024
Efficacy of Polyethylene Glycol Electrolyte Powder Combined With Linaclotide for Colon Cleansing in Patients With Chronic Constipation Undergoing Colonoscopy: A Multicenter, Single-Blinded, Randomized Controlled Trial.
2024
Efficacy of linaclotide in combination with polyethylene glycol for bowel preparation in Chinese patients undergoing colonoscopy polypectomy: protocol for a randomised controlled trial.
2024
Evaluation of the efficacy of polyethylene glycol in combination with different doses of linaclotide in a fractionated bowel preparation for colonoscopy: a prospective randomized controlled study.
2024
Examining linaclotide for the treatment of chronic idiopathic constipation.
2024
Linaclotide
2024
Linaclotide for functional constipation in paediatric patients: phase III results.
2024
Linaclotide for paediatric functional constipation.
2024
Randomized controlled trial of linaclotide in children aged 6-17 years with functional constipation.
2024
Renoprotective effects of laxative linaclotide: Inhibition of acute kidney injury and fibrosis in a rat model of renal ischemia-reperfusion.
2024
Safety and efficacy of linaclotide in children aged 2-5 years with functional constipation: Phase 2, randomized study.
2024
Safety and efficacy of linaclotide in children aged 7-17 years with irritable bowel syndrome with constipation.
2024
Ten years of successful linaclotide treatment in a patient with intestinal pseudo-obstruction due to Ehlers-Danlos syndrome.
2024
The Effects of Combined Use of Linaclotide and Polyethylene Glycol Electrolyte Powder in Colonoscopy Preparation for Patients With Chronic Constipation.
2024
The gut microbiota participates in the effect of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C): a multicenter, prospective, pre-post study.
2024
A New Regioselective Synthesis of the Cysteine-Rich Peptide Linaclotide.
2023
A novel ultra-low-volume regimen combining 1 L polyethylene glycol and linaclotide versus 2 L polyethylene glycol for colonoscopy cleansing in low-risk individuals: a randomized controlled trial.
2023
Cost impact of incorporating linaclotide into low-volume colonoscopy preparation.
2023
Editorial: repurposed linaclotide and the quest for abdominal pain management in irritable bowel syndrome.
2023
Linaclotide (Linzess) for functional constipation.
2023
Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials.
2023
Microbiota-derived butyrate dampens linaclotide stimulation of the guanylate cyclase C pathway in patient-derived colonoids.
2023
Cost-Effectiveness of Linaclotide Compared to Osmotic Laxatives in the Treatment of Irritable Bowel Syndrome with Constipation in China.
2022
Effects of linaclotide in the treatment of chronic constipation and irritable bowel syndrome with constipation: a meta-analysis.
2022
Efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation: Chinese sub-cohort analysis of a phase III, randomized, double-blind, placebo-controlled trial.
2022
Linaclotide for treating patients with irritable bowel syndrome with predominant constipation: a multicentre study of real-world data in China.
2022
Linaclotide utilization and potential for off-label use and misuse in three European countries.
2022
Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System.
2021
Improving the Gastrointestinal Stability of Linaclotide.
2021
Linaclotide for the treatment of refractory lower bowel manifestations of systemic sclerosis.
2021
Polyethylene glycol combined with linaclotide is an effective and well-tolerated bowel preparation regimen for colonoscopy: an endoscopist-blinded, randomized, controlled trial.
2021
Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation.
2021
The Use of Linaclotide in Children with Functional Constipation or Irritable Bowel Syndrome: A Retrospective Chart Review.
2021
[Efficacy and Safety of Linaclotide in Elderly Patients].
2021
Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study.
2020
Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis.
2020
Tadalafil versus linaclotide in gastrointestinal dysfunction and depressive behavior in constipation-predominant irritable bowel syndrome.
2020
The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease.
2020
Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive and extra-digestive symptoms.
2019
Effectiveness and tolerability of linaclotide in the treatment of IBS-C in a "real-life" setting: Results from a Portuguese single-center study.
2019
High-dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, double-blind, placebo-controlled study with a long-term open-label extension study in Japan.
2019
Linaclotide increases cecal pH, accelerates colonic transit, and increases colonic motility in irritable bowel syndrome with constipation.
2019
Linaclotide treatment reduces endometriosis-associated vaginal hyperalgesia and mechanical allodynia through viscerovisceral cross-talk.
2019
Long-term treatment with linaclotide of intestinal pseudo-obstruction secondary to Ehlers-Danlos syndrome.
2019
Multicentre, non-interventional study of the efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in primary, secondary and tertiary centres: the Alpine study.
2019
Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis.
2019
Single-Dose Linaclotide Is Equal in Efficacy to Polyethylene Glycol for Bowel Preparation Prior to Capsule Endoscopy.
2019
The Impact of Stool Consistency on Bowel Movement Satisfaction in Patients With IBS-C or CIC Treated With Linaclotide or Other Medications: Real-World Evidence From the CONTOR Study.
2019
[Pharmacological and clinical profile of linaclotide (Linzess<sup>®</sup>), a novel therapeutic agent for irritable bowel syndrome with constipation and chronic constipation].
2019
A randomized controlled and long-term linaclotide study of irritable bowel syndrome with constipation patients in Japan.
2018
Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction.
2018
Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.
2018
Dose-finding study of linaclotide in Japanese patients with chronic constipation: A phase II randomized, double-blind, and placebo-controlled study.
2018
Efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in a real‑world setting - results from a German noninterventional study.
2018
Efficacy of linaclotide in irritable bowel syndrome with constipation: Real-world data.
2018
Health Care Resource Use and Costs Pre- and Post-Treatment Initiation With Linaclotide: Retrospective Analyses of a U.S. Insured Population.
2018
Linaclotide Attenuates Visceral Organ Crosstalk: Role of Guanylate Cyclase-C Activation in Reversing Bladder-Colon Cross-Sensitization.
2018
Linaclotide for the treatment of chronic constipation.
2018
Linaclotide improves gastrointestinal transit in cystic fibrosis mice by inhibiting sodium/hydrogen exchanger 3.
2018
Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
2018
Linaclotide inhibits colonic and urinary bladder hypersensitivity in adult female rats following unpredictable neonatal stress.
2018
Long-term results of linaclotide in the treatment of constipation-type irritable bowel syndrome.
2018
Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
2018
Randomized, double-blind, placebo-controlled study vs data in the daily practice using linaclotide in patients with irritable bowel syndrome with constipation.
2018
Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention.
2017
Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-II-dependent trafficking of CFTR in the intestine.
2017
Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report.
2017
Cost-effectiveness of linaclotide compared to antidepressants in the treatment of irritable bowel syndrome with constipation in Scotland.
2016
Economic Evaluation of Linaclotide for the Treatment of Adult Patients With Chronic Idiopathic Constipation in the United States.
2016
A comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosa.
2015
Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
2015
Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial.
2015
MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux.
2015
Clarification of linaclotide pharmacology presented in a recent clinical study of plecanatide.
2014
Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis.
2014
Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.
2014
Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials.
2014
Linaclotide. A bacterial enterotoxin derivative with a laxative action, nothing more.
2014
Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome.
2014
Linaclotide: a review of its use in the treatment of irritable bowel syndrome with constipation.
2014
Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C.
2014
Review article: Linaclotide for the management of irritable bowel syndrome with constipation.
2014
The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials.
2014
A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
2013
An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials.
2013
Challenges of managing pain in constipation-predominant IBS: clinical perspectives on antinociceptive actions of linaclotide.
2013
Constella™(EU)-Linzess™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs.
2013
Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
2013
Linaclotide for constipation-predominant IBS.
2013
Linaclotide for treatment of irritable bowel syndrome--the view of European regulators.
2013
Linaclotide in the treatment of patients with irritable bowel syndrome and constipation - analysis of an opportunity.
2013
Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.
2013
Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome.
2013
Linaclotide-a novel secretagogue in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
2013
Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation.
2013
Linaclotide: a new option for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation in adults.
2013
Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation.
2013
Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
2013
Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
2013
[Joint Statement of the German Society for Digestive and Metabolic Diseases (DGVS), the German Society for Neurogastroenterology and motility (DGNM) and the German Society for Internal Medicine (DGIM) for linaclotide-benefit assessment of the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with § 35a SGB V (dossier evaluation)].
2013
A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
2012
Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors.
2012
Elvitegravir/cobicistat, mirabegron, and linaclotide.
2012
Linaclotide
2012
Linaclotide (Linzess) for constipation.
2012
Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
2012
Linaclotide in the management of gastrointestinal tract disorders.
2012
Linaclotide: first global approval.
2012
Linaclotide: promising IBS-C efficacy in an era of provisional study endpoints.
2012
Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.
2011
Linaclotide: a novel approach to the treatment of irritable bowel syndrome.
2011
Optimized Fmoc solid-phase synthesis of the cysteine-rich peptide linaclotide.
2011
The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide.
2011
Two randomized trials of linaclotide for chronic constipation.
2011
Constipation: Linaclotide--a stimulating new drug for chronic constipation.
2010
Efficacy of linaclotide for patients with chronic constipation.
2010
Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.
2010
Linaclotide - a secretagogue and antihyperalgesic agent - what next?
2010
Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation.
2010
Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.
2010
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
2010
Molecule of the month. Linaclotide acetate.
2010
Pilot study on the effect of linaclotide in patients with chronic constipation.
2009
Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
2007
Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation.
2007
Linaclotide
2006